Updates are available Correction dated 2025-12-30
Click to view Correction: https://doi.org/10.1007/s40272-025-00729-y
-
Authors
González-Llorens, Nuria https://orcid.org/0000-0003-0550-4665
Yau, Daphne https://orcid.org/0000-0002-3559-6479
León, María Clemente https://orcid.org/0000-0002-3721-5043
Demirbilek, Huseyin https://orcid.org/0000-0001-6374-5884
Banerjee, Indraneel https://orcid.org/0000-0003-4280-7470
Shah, Pratik https://orcid.org/0000-0002-4402-8297
- License Information
-
More Information
Article History
Received: 18 May 2025
Accepted: 9 October 2025
First Online: 7 November 2025
Change Date: 24 December 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct the organization name Children’s Hyperinsulinism Charity in the Acknowledgements and Declarations sections.
Change Date: 30 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40272-025-00729-y
Declarations
:
: MC participated as principal investigator and NGL as sub-investigator in the clinical trials (phase II and phase III) for ersodetug funded by Rezolute. HD participated as principal investigator in the clinical trials (phase II and phase III) for ersodetug funded by Rezolute. He is an associate editor for Frontiers in Endocrinology. He is involved with the patient charities Congenital Hyperinsulinism Charity, Turkiye, and Congenital Hyperinsulinism International. IB received grant funding for clinical trials by Zealand Pharma, Rezolute Pharma, Crinetics Pharma and Hanmi Pharma. IB was the Chair of the NIHR Paediatric Endocrinology Clinical Studies Group and is a co-chair of the UK Children’s Hospital Alliance Research Oversight Group. He is an associate editor for Frontiers in Endocrinology. IB is involved with the patient charities Children’s Hyperinsulinism Charity, UK, and Congenital Hyperinsulinism International. PS is the founder of Congenital Hyperinsulinism India Association (CHIA), and is involved with the patient charities Children’s Hyperinsulinism Charity, UK (as Patron), and Congenital Hyperinsulinism International. He has also been involved with clinical trials by Zealand Pharma and Rezolute Pharma. He is a guest associate editor for Frontiers in Endocrinology. DY participated as principal investigator in the phase III clinical trial funded by Rezolute. She is involved with the patient charity Congenital Hyperinsulinism International.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: NGL and PS designed, developed and wrote the manuscript. IB, HD, MC, and DY wrote the manuscript. NGL created Fig. . All authors have read and approved the final version of the manuscript, and agree to be accountable for the work.
